Research Progress of Pluronic as a Drug Delivery System for Reversing Multidrug Resistance of Tumors
LI Wei-nan1, SUN Jia-lin2 , GUAN Qing-xia1, WANG Yan-hong1*
1. Department of Pharmacy, Heilongjiang University of Chinese Medicine, Herbin 150040, China; 2. Department of Biotechnology, Heilongjiang Vocational College for Nationalities, Harbin 150040, China
Abstract��Pluronic is a kind of formulation material with both hydrophilic and hydrophobic properties. Drug delivery system with pluronic as a carrier is one of the most promising drug delivery systems for reversing multidrug resistance of tumors. In this paper, we have summarized the target drug delivery systems of Pluronic in the inhibition of tumor drug resistance, especially the application of Pluronic in the delivery system.
��ΰ��,�����,����ϼ,����. ��ת������ҩ��ҩ�Ե�������˰���ҩ�ﴫ��ϵͳ[J]. �й�ҩѧ��־, 2016, 51(15): 1270-1273.
LI Wei-nan, SUN Jia-lin , GUAN Qing-xia, WANG Yan-hong. Research Progress of Pluronic as a Drug Delivery System for Reversing Multidrug Resistance of Tumors. Chinese Pharmaceutical Journal, 2016, 51(15): 1270-1273.
JULIANO R L, LING V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochim Biophys Acta, 1976, 455(1):152-162.
[2]
ALAKHOVA D Y, KABANOV A V. Pluronics and MDR reversal: an update[J]. Mol Pharm, 2014, 11(8):2566-2578.
[3]
MINKO T, RODRIGUEZ-RODRIGUEZ L, POZHAROV V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers[J]. Adv Drug Deliv Rev, 2013, 65(13-14):1880-1895.
[4]
KABANOV A V, BATRAKOVA E V, ALAKHOV V Y. Pluronic block copolymers for overcoming drug resistance in cancer[J]. Adv Drug Deliv Rev, 2002, 54(5):759-779.
[5]
MU L Q, HU X B, HU Y Y, et al. Advances in the study of overcoming multidrug resistance in cancer by pluronic block copolymers[J]. Chin Hosp Pharm J (�й�ҽԺҩѧ��־), 2014(34):1781-1784.
[6]
BAGRIJ T, KLOKOUZAS A, HLADKY S B, et al. Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1 [J]. Biochem Pharmacol, 2001, 62(2):199-206.
[7]
KUNJACHAN S, RYCHLIK B, STORM G, et al. Multidrug resistance: physiological principles and nanomedical solutions[J]. Adv Drug Deliv Rev, 2013, 65(13-14):1852-1865.
[8]
BATRAKOVA E V, LI S, BRYNSKIKH A M, et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers[J]. J Controlled Release, 2010, 143(3):290-301.
[9]
HUANG S J, SUN S L, FENG T H, et al. Folate-mediated chondroitin sulfate-Pluronic 127 nanogels as a drug carrier[J]. Eur J Pharm Sci, 2009, 38(1):64-73.
[10]
BATRAKOVA E V, LI S, LI Y, et al. Ditribution kinetics of a micelle-forming block copolymer Pluronic P85[J]. J Controlled Release, 2004, 100(3):389-397.
[11]
PEC E A, WOUT Z G, JOHNSTON T P. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat[J]. J Pharm Sci, 1992, 81(7):626-630.
[12]
SONG H, HE R, WANG K, et al. Anti-HIF-1alpha antibody-conjugated pluronic triblock copolymers encapsulated with Paclitaxel for tumor targeting therapy[J]. Biomaterials, 2010, 31(8):2302-2312.
[13]
BATRAKOVA E, LEE S, LI S, et al. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells[J]. Pharm Res, 1999, 16(9):1373-1379.
[14]
WANG Y Z, FANG X L, LI Y J, et al. Preparation, characterization of paclitaxel loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor[J]. Acta Pharm Sin (ҩѧѧ��), 2008, 43(6):640-646.
[15]
NGUYEN D H, LEE J S, BAE J W, et al. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice[J]. Int J Pharm, 2015, 495(1):329-335.
[16]
ZHAO Y Z, SUN C Z, LU C T, et al. Characterization and anti-tumor activity of chemical conjugation of doxorubicin in polymeric micelles (DOX-P) in vitro[J]. Cancer Lett, 2011, 311(2):187-194.
[17]
CHEN Y, ZHANG W, HUANG Y, et al. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor[J]. Int J Pharm, 2015, 488(1-2):44-58.
[18]
ZHANG W, SHI Y, CHEN Y Z, et al. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors[J]. Biomaterials, 2011, 32(11):2894-2906.
[19]
CHO H J, YOON H Y, KOO H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic P85 for tumor-targeted delivery of docetaxel[J]. Biomaterials, 2011, 32(29):7182-7190.
[20]
JI X F, GAO Y, CHEN L L, et al. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance[J]. Int J Pharm, 2012, 422(1-2):391-397.
[21]
SHEN J, YIN Q, CHEN L, et al. Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complexnanoparticles to overcome drug resistance in lung cancer[J]. Biomaterials, 2012, 33(33):8613-8624.
[22]
GU Z J, WANG M, FANG Q Y, et al. Inhibition of MCF-7/ADR cells by DOX-loaded pluronic-attached PAMAM dendrimer conjugate[J]. Acta Pharm Sin (ҩѧѧ��), 2014, 49(8):1188-1193.
[23]
VELLUTO D L, THOMAS S N, SIMEONI E, et al. PEG-b-PPS-b-PEI micelles and PEG-b-PPS/PEG-b-PPS-b-PEI mixed micelles as non-viral vectors for plasmid DNA:tumor immunotoxicity in B16F10 melanoma[J]. Biomaterials, 2011, 32(36):9839-9847.
[24]
LIU C, YU W, CHEN Z, et al. Enhanced gene transfection efficiency in CD13-positive vascular endothelial cells with targeted poly(lactic acid)-poly(ethylene glycol) nanoparticles through caveolae-mediated endocytosis[J]. J Controlled Release, 2011, 151(2):162-175.
[25]
NGUYEN H K, LEMIEUX P, VINOGRADOV S V, et al. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents[J]. Gene Ther, 2000, 7(2):126-138.
[26]
GU J, FANG X, HAO J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery[J]. Biomaterials, 2015, 45:99-114.
[27]
HONG W, CHEN D W, ZHANG X J, et al. Reversing multidrug resistance by intracellular delivery of Pluronic P85 unimers[J]. Biomaterials, 2013, 34(37):9602-9614.
[28]
OERLEMANS C, BULT W, BOS M, et al. Polymeric micelles in anticancer therapy:targeting, imaging and triggered release[J]. Pharm Res, 2010, 27(12):2569-2589.
[29]
REYA T, MORRISON S J, CLARKE M F, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001, 414(6859):105-111.
[30]
ZHAO Y, ALAKHOVA D Y, KABANOV A V, et al. Can nanomedicines kill cancer stem cells[J]. Adv Drug Deliv Rev, 2013, 65(13-14):1763-1783.
[31]
ALAKHOVA D, YZHAO Y, LI S, et al. Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia[J]. PLoS One, 2013, 8(8):e72238.
2016, Vol. 51 
